Figure 1
From: Establishment of patient derived xenografts as functional testing of lung cancer aggressiveness
Analysis of PDXs characteristics. (A) Parental tumour diagnosis was maintained in all established PDX. Pictures show a representative example of 1 ACC- and 1 SCC-derived PDXs. (B) Immunohistochemistry markers analysis confirmed that our PDXs platform generally maintained the same expression pattern of parental tumours, picture shows a representative example of a TTF1 expressing ADC-derived PDX. (C) PDXs stromal content was generally lower compared to parental tumours, especially at P > 10. However, stromal components were always more represented in PDXs than in cell line derived xenografts (average stromal component: 22 ± 12% in parental tumours, 15 ± 7% in P ≤ 10 and 10 ± 7% in P > 10, n = 10; 4.2 ± 1.012% in lung cancer cell line xenografts, n = 5). (D) In PDX LT220 complete loss of TTF1 and marked acquisition of vimentin and Ki67 labelling index was observed along with the appearance of spindle cells. ADC = Adenocarcinoma, SCC = Squamous Cell; (E) CD133+ cell percentage was also maintained in PDX models (n = 17, p = 0.0005, r2 = 0.568); (F) PDXs were differently responsive to cisplatin treatment (5 mg/Kg once a week for three weeks), models were considered responsive when at least a partial response (PR, median of four tumors) was reached. Mean Overall Survival of patients treated after surgery and from whom a responsive PDX was derived (R-treated) were higher than that of patients from whom a non responsive PDX was derived (NR-treated; 27.667 ± 7.753 months n = 3 and 8.5 ± 3.019 months n = 6, respectively). MCR: maintained complete response; CR: complete response; PR: partial response; SD: stable disease; PD: progression of disease.
